Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from generic drugs increased due to selective concentration of resources, contributions from recently launched products, and the replacement of certain products following the introduction of selected medical treatment for long-listed products. Revenue from core products and new drugs declined due in part to the impact of drug price revisions. Revenue from clinical laboratory reagents increased as DropScreen gained wider adoption.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥33,090 million (YoY +1.6%) |
| Operating profit | ¥179 million (YoY -70.4%) |
| Ordinary income | ¥227 million (YoY -48.6%) |
| Profit attributable to owners of the parent | ¥198 million (YoY -32.8%) |
| Net income per share | ¥54.81 |
| Operating Margin | 0.5 |
| Equity ratio | End of the current fiscal period 39 / End of previous period 38.4 |
| Total assets | ¥49,978 million |
| Net assets | ¥19,510 million |
| Cash flows from operating activities | ¥620 million |
| Cash flows from investing activities | ¥-661 million |
| Cash flows from financing activities | ¥-1,673 million |
| Cash and cash equivalents at end of period | ¥5,342 million |
| Full-year earnings forecast | Net Sales ¥35,000 million (YoY +5.8%) / Operating profit ¥250 million (YoY +39.0%) / Ordinary income ¥100 million (YoY -56.1%) / Profit attributable to owners of the parent ¥60 million (YoY -69.7%) |
| Annual Dividend Forecast | ¥50 → ¥50（0.0%） |
| Payout ratio | 91.2 |
| Segment revenue | Pharmaceuticals Business ¥31,868 million (YoY +1.5%), Other ¥1,222 million (YoY +3.1%) |
| Segment profit | Pharmaceuticals Business ¥187 million (YoY -63.1%), Other ¥-7 million |
| Depreciation and amortization | ¥1,559 million |
| Impairment loss | ¥0 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥157 million / Extraordinary loss Impairment Loss on Investment Securities ¥163 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person None |
| Issued Shares at Period-End | 4,261,420 Shares |
| Treasury Shares at Period-End | 636,664 Shares |
| Factors Behind Changes in Business Performance | Revenue from generic drugs increased due to selective concentration of resources, contributions from recently launched products, and the replacement of certain products following the introduction of selected medical treatment for long-listed products. Revenue from core products and new drugs declined due in part to the impact of drug price revisions. Revenue from clinical laboratory reagents increased as DropScreen gained wider adoption. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from core products and new drugs declined due in part to the impact of drug price revisions. The Other business also shifted from operating profit of ¥99 million to an operating loss of ¥7 million. The company stated that, while the earnings environment remains challenging amid continued drug price reductions, it focused on expanding sales of recently launched generic drugs and profitable products, as well as the clinical laboratory reagent DropScreen.